Asuragen said today that it has received US Food and Drug Administration clearance for its cGMP-manufactured sample collection and cellular RNA preservation device.

The device, called RNARetain, was first cleared by FDA in 2007 in conjunction with Agendia's MammaPrint breast cancer test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.